Gout and refractory hyperuricemia: cross-border specialty drug access for international patients

Quick orientation

Gout affects an estimated 1 to 4 percent of adults globally, with substantial regional variation. Refractory gout (chronic, tophaceous, treatment-failure disease) is a smaller subset.

Typical age of onset. Most commonly diagnosed in adults aged 40 and older, with male predominance until later life.

Severity tiers. Severity ranges from intermittent acute attacks to chronic tophaceous disease with joint destruction and renal complications.

Why specialty drugs for Gout and refractory hyperuricemia are hard to access internationally

Standard urate-lowering agents are broadly available. Krystexxa (pegloticase) and Sotyktu (tirzepatide for adjacent metabolic disease) and emerging agents for refractory disease have narrower global registration. Patients with refractory tophaceous gout often face limited options locally.

Treatments approved by the FDA

• Krystexxa (pegloticase) — FDA approval: 2010. Mechanism: Recombinant pegylated uricase. Route: Intravenous infusion every 2 weeks. US WAC ballpark: Approximately USD 30,000 to 45,000 per infusion. Country pricing: UAE · Saudi Arabia · India · Egypt.

Cross-border pathways used for Gout and refractory hyperuricemia

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm refractory disease per ACR criteria.
• Document failure or intolerance of conventional urate-lowering therapy.
• Pre-treatment G6PD screening is required before pegloticase.
• Co-administration with immunomodulators may reduce infusion reactions; specialist guidance.
• Rheumatologist co-management is recommended.

Common questions

Will Krystexxa lower my uric acid?

Pegloticase produces a rapid and substantial reduction in serum urate in responders.

Why is G6PD testing required?

Pegloticase can cause hemolysis in G6PD-deficient patients. Screening is mandatory before initiation.

How long is treatment?

Treatment is generally limited in duration; non-responders are discontinued.

Is it available locally?

Registration varies by country. We confirm by destination.

What documents are required?

Rheumatologist's prescription, urate trend, G6PD result, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Gout and refractory hyperuricemia, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Gout and refractory hyperuricemia

Reserved for you.